Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

The next frontier of molecular medicine: Delivery of therapeutics

Nature Medicine volume 4, pages 655–657 (1998)Cite this article

Despite exciting progress in the biology underlying a variety of proposed molecular medicines, an unmet challenge Remains—delivery. This problem, how to better target the new generation of therapeutics, cuts across all diseases. The solution offers unprecedented opportunities for multidisciplinary teams of bioengineers to work with biological and medical scientists to realize the fruits of our nation's investment in molecular and cellular medicine.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jain, R.K. Delivery of Molecular Medicine to Solid Tumors. Science 271, 1079–1080 (1996).

    Article  CAS  Google Scholar 

  2. Klausner, R.D., The Nation's Investment in Cancer Research: A Budget Proposal for Fiscal Year 1999. National Cancer Institute (September 1997).

    Google Scholar 

  3. Jain, R.K. 1996 Eugene M. Landis Award Lecture: Delivery of Molecular and Cellular Medicine to Solid Tumors. Microcirculation 4, 1–23 (1997).

    Article  CAS  Google Scholar 

  4. Jain, R.K., Schlenger, K., Höckel, M. & Yuan, F. Quantitative Angiofenesis Assays: Progress and Problems. Nature Med. 3, 1203–1208 (1997).

    Article  CAS  Google Scholar 

  5. Fidler, I.J. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. 87, 1588–1592 (1995).

    Article  CAS  Google Scholar 

  6. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 6, 353–64 (1996).

    Article  Google Scholar 

  7. Kerbel, R.S. A cancer therapy resistant to resistance. Nature 390, 335–336 (1997).

    Article  CAS  Google Scholar 

  8. Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380 (1998).

    Article  CAS  Google Scholar 

  9. Baxter, L.T., Zhu, H., Butler, W.F., Mackensen, D.G. & Jain, R.K. Biodistribution of monoclonal antibodies: scale-up from mouse to man using a physiologically-based pharmacokinetic model. Cancer Res. 55, 4611–4622 (1995).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 02114, USA

    Rakesh K. Jain

Authors
  1. Rakesh K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jain, R. The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 4, 655–657 (1998). https://doi.org/10.1038/nm0698-655

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0698-655

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing